Navigation Links
Immucor Schedules First Quarter Earnings Release and Conference Call
Date:9/28/2007

NORCROSS, Ga., Sept. 28 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that it expects to release its first quarter earnings on Wednesday, October 3, 2007, after the close of regular trading hours, and then host a conference call on Thursday, October 4, 2007 at 8:30 AM (EDT) to review the results. Investors are invited to participate in this conference call, with Dr. Gioacchino De Chirico, President and Chief Executive Officer, Patrick D. Waddy, Chief Financial Officer and Edward L. Gallup, consultant. The call will focus on the results for the first quarter and general business trends. The earnings release will be posted on Immucor's website, as well as any material financial information that may be discussed by Dr. De Chirico, Mr. Waddy or Mr. Gallup during this call that is not contained in the earnings release. Both the earnings release and the additional financial information, if any, will be posted as soon as practicable after the call on the investor news section of Immucor's website. To access this information once posted, go to Immucor's website at http://www.immucor.com and click on "About Us - Press Releases."

To participate in the telephone conference call, dial 1-800-593-0187 and passcode BLUD. Replays of the conference call will be available for one week beginning at 12:00 noon on October 4th by calling 1-888-484-8256. Beginning October 11, 2007, audio of the conference call or a transcript of the audio will be available on the "About Us - Press Releases" page of the Immucor website.

For more information on Immucor, please visit our website at http://www.immucor.com.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.


'/>"/>
SOURCE Immucor
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Shorter Radiation Schedules Found To Be More Effective For Patients With Breast Cancer
2. Vaccination Schedules Rates among Canadian Kids Dip Low
3. UP Government Fixes Work Schedules for Provincial Medical Service Doctors
4. First Vaccine Designed for Africa Cleared for Testing in Humans
5. Infant receives first bloodless liver transplant
6. Oracle Corp. to help build worlds first "Digital Hospital"
7. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
8. First human clone is near
9. First Artificial Heart patient has Major setback
10. FDA approves first pocket-sized EKG machine
11. First head-to-head trials of once weekly Fosamax and Actonel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through ... a partner for the Tamika Catchings Legacy Tour that will commemorate the ... in hardwood basketball surfaces in all forms and levels of the game, Connor Sports ...
(Date:5/26/2016)... PA (PRWEB) , ... May 26, 2016 , ... ... and one that has a significant negative impact on long-term patient survival, reports ... date. The results, published online this week in the Journal of Thoracic and ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Israel , May 27, 2016 ... an innovative biopharmaceutical company focused on late-stage drug ... Dexcel Pharma of pivotal batches required ... and Drug Administration (FDA). This follows Kitov,s ... Phase III trial successfully met its primary efficacy ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
Breaking Medicine Technology: